How can we accelerate COVID-19 vaccine discovery?

Published on May 31, 2021in Expert Opinion on Drug Discovery4.887
· DOI :10.1080/17460441.2021.1935861
Giulia Russo27
Estimated H-index: 27
(University of Catania),
Valentina Di Salvatore3
Estimated H-index: 3
(University of Catania)
+ 3 AuthorsFrancesco Pappalardo23
Estimated H-index: 23
(University of Catania)
Sources
Abstract
📖 Papers frequently viewed together
10 Citations
4 Citations
References14
Newest
#1Priyasha De (Manipal University)H-Index: 1
#2Ishita Chakraborty (Manipal University)H-Index: 2
Last. Nirmal Mazumder (Manipal University)H-Index: 11
view all 4 authors...
Abstract Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the pandemic coronavirus disease 2019 (Covid-19) has claimed more than a million lives. Various in silico, in vitro, and in vivo studies are being conducted to understand the effect of SARS-CoV-2 on the cellular metabolism of humans and the various drugs and drug-targets that may be used. In this review, we discuss protein-protein interactions (PPIs) between viral and human proteins as well as viral tar...
Source
#1Ben Hu (CAS: Chinese Academy of Sciences)H-Index: 18
#2Hua Guo (CAS: Chinese Academy of Sciences)H-Index: 8
Last. Zhengli Shi (CAS: Chinese Academy of Sciences)H-Index: 64
view all 4 authors...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute respiratory disease, named 'coronavirus disease 2019' (COVID-19), which threatens human health and public safety. In this Review, we describe the basic virology of SARS-CoV-2, including genomic characteristics and receptor use, highlighting its key difference from previously known coronaviruses. We summarize current knowled...
222 CitationsSource
#1Andrew J. Pollard (University of Oxford)H-Index: 86
#2Else M Bijker (University of Oxford)H-Index: 2
Immunization is a cornerstone of public health policy and is demonstrably highly cost-effective when used to protect child health. Although it could be argued that immunology has not thus far contributed much to vaccine development, in that most of the vaccines we use today were developed and tested empirically, it is clear that there are major challenges ahead to develop new vaccines for difficult-to-target pathogens, for which we urgently need a better understanding of protective immunity. Mor...
11 CitationsSource
#1Abba B. Gumel (ASU: Arizona State University)H-Index: 41
#2Enahoro Iboi (Spelman College)H-Index: 8
Last. Elamin H. Elbasha (MSD: Merck & Co.)H-Index: 30
view all 4 authors...
Abstract The novel coronavirus (COVID-19) pandemic that emerged from Wuhan city in December 2019 overwhelmed health systems and paralyzed economies around the world. It became the most important public health challenge facing mankind since the 1918 Spanish flu pandemic. Various theoretical and empirical approaches have been designed and used to gain insight into the transmission dynamics and control of the pandemic. This study presents a primer for formulating, analysing and simulating mathemati...
11 CitationsSource
#1Giulia Russo (University of Catania)H-Index: 13
#1Giulia Russo (University of Catania)H-Index: 27
Last. Francesco Pappalardo (University of Catania)H-Index: 23
view all 7 authors...
SARS-CoV-2 is a severe respiratory infection that infects humans. Its outburst entitled it as a pandemic emergence. To get a grip on this outbreak, specific preventive and therapeutic interventions are urgently needed. It must be said that, until now, there are no existing vaccines for coronaviruses. To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline...
2 CitationsSource
#1Rupal Ojha (Central University of Rajasthan)H-Index: 11
#2Nidhi Gupta (Central University of Rajasthan)H-Index: 4
Last. Vijay Kumar Prajapati (Central University of Rajasthan)H-Index: 28
view all 7 authors...
The ongoing enigmatic COVID-19 outbreak, first reported from Wuhan, China, on last day of the year 2019, which has spread to 213 countries, territories/areas till 28th April, 2020, threatens hundreds of thousands human souls. This devastating viral infection has stimulated the urgent development of viable vaccine against COVID-19 across the research institutes around the globe. The World Health Organization (WHO) has also confirmed that the recent pandemic is causing Public Health Emergency of I...
14 CitationsSource
#1Maria Tsikala Vafea (Brown University)H-Index: 1
#2Eleftheria Atalla (Brown University)H-Index: 4
Last. Eleftherios Mylonakis (Brown University)H-Index: 1
view all 7 authors...
The COVID-19 pandemic has caused an unprecedented health and economic worldwide crisis Innovative solutions are imperative given limited resources and immediate need for medical supplies, healthcare support and treatments The purpose of this review is to summarize emerging technologies being implemented in the study, diagnosis, and treatment of COVID-19 Key focus areas include the applications of artificial intelligence, the use of Big Data and Internet of Things, the importance of mathematical ...
29 CitationsSource
#1Divya Hosangadi (Johns Hopkins University)H-Index: 6
#2Kelsey Lane Warmbrod (Johns Hopkins University)H-Index: 3
Last. Nancy Connell (Johns Hopkins University)H-Index: 6
view all 9 authors...
12 CitationsSource
#1Alexander Holderied (Charité)H-Index: 1
#2Franziska Kraft (LMU: Ludwig Maximilian University of Munich)H-Index: 5
Last. Hans-Joachim Anders (LMU: Ludwig Maximilian University of Munich)H-Index: 89
view all 5 authors...
Background In the past years evidence has been growing about the interconnection of chronic kidney disease and acute kidney injury. The underlying pathophysiological mechanisms remain unclear. We hypothesized, that a threshold ischemia time in unilateral ischemia/reperfusion injury sets an extent of ischemic tubule necrosis, which as “point of no return” leads to progressive injury. This progress is temporarily associated by increased markers of inflammation and results in fibrosis and atrophy o...
6 CitationsSource
#1Ruei-Min Lu (AS: Academia Sinica)H-Index: 7
#2Yu‐Chyi Hwang (AS: Academia Sinica)H-Index: 2
Last. Han-Chung Wu (AS: Academia Sinica)H-Index: 34
view all 7 authors...
It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved. Current antibody drugs have increasingly fewer adverse effects due to their high specificity. As a result, therapeutic antibodies have become the predominant class of new drugs developed in recent years. Over the past five years, antibodies have become the best-selling drugs in...
177 CitationsSource
Cited By0
Newest